Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme Recovery Is Taking Off, Termeer Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Ahead of an important investor meeting in New York on Friday, Genzyme reported third quarter sales showing signs that drug supply constraints are improving.

You may also be interested in...



Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business

Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.

Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business

Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.

Sanofi/Genzyme Saga: War Before Peace?

Unless a white knight bidder emerges to thwart Sanofi-Aventis' attempt to acquire Genzyme, and soon, the Cambridge-Mass.-based biotech's best negotiating tactic may be stalling.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel